Background illustration for clinical trials search

Paid Clinical Trials Fargo

Discover 170 paid clinical trials in Fargo, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 170

The Minimalist Trial-2

for

HPV-Related Oropharynx Squamous Cell Carcinoma

Location: Fargo ND, Sioux Falls SD, St Louis MO

Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06702033

Phase2, Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for

Diffuse Large B-Cell Lymphoma

Location: Fargo ND, Sioux Falls SD, Madison WI, Topeka KS,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase3, Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for

B-cell Acute Lymphoblastic Leukemia,

Location: Fargo ND, Sioux Falls SD, Iowa City IA, Kansas City MO,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 25

Code: NCT06395103

Phase1, Phase2, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,

Location: Fargo ND, Grand Forks ND, Bemidji MN, Brainerd MN,

Sponsor: NRG Oncology

Sex: Male

Age: 18+

Code: NCT05946213

Phase3, Recruiting

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for

Myelodysplastic Syndrome

Location: Fargo ND, Brainerd MN, Deer River MN, Hibbing MN,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase2, Recruiting

Family Communications After Genetic Testing

for

Colon Adenocarcinoma, Colorectal Adenocarcinoma,

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07143487

Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

for

Anatomic Stage II Breast Cancer AJCC v8,

Location: Fargo ND, Detroit Lakes MN, Brainerd MN, Deer River MN,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07391774

Phase3, Recruiting

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

for

Locally Advanced Pancreatic Adenocarcinoma,

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06998940

Phase3, Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for

Locally Advanced Urothelial Carcinoma,

Location: Fargo ND, Aberdeen SD, Brainerd MN, Deer River MN,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06524544

Phase3, Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Fargo ND, Deer River MN, Hibbing MN, Sandstone MN,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for

Prostate Cancer (Adenocarcinoma)

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06592924

Phase3, Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

for

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements,

Location: Fargo ND, Brainerd MN, Deer River MN, Hibbing MN,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06649812

Phase2, Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for

Castration-Resistant Prostate Carcinoma,

Location: Fargo ND, Brainerd MN, Saint Cloud MN, Duluth MN,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06632977

Phase2, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Fargo ND, Brainerd MN, Deer River MN, Hibbing MN,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for

Intracranial Meningioma, Recurrent Meningioma,

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT02523014

Phase2, Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

for

Metastatic Small Intestinal Adenocarcinoma,

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04205968

Phase2, Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

for

Smoldering Plasma Cell Myeloma

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 18+

Code: NCT03937635

Phase3, Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for

Breast Carcinoma, Colorectal Carcinoma,

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT06418204

Recruiting

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

for

Cigarette Smoking-Related Carcinoma

Location: Fargo ND, Detroit Lakes MN, Park Rapids MN, Brainerd MN,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT05008848

Phase3, Recruiting

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

for

Metastatic Malignant Neoplasm in the Liver,

Location: Fargo ND, Detroit Lakes MN, Fosston MN, Park Rapids MN,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05040360

Phase2, Recruiting

Paid Clinical Trials Fargo

Filter results

The Minimalist Trial-2

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Interested in new trials?

Family Communications After Genetic Testing

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors